A strategic corporate venture capital fund makes equity investments in startup companies developing innovative therapeutic products and drug-enabling platform technologies with clear potential to benefit cancer patients. Investment size is flexible depending on the opportunity. In addition to traditional equity investments, the firm may consider option-based structures and spin-outs. The firm seeks opportunities primarily in US and Europe.
The firm focuses on early-stage opportunities, generally from research through pre-IND, targeting first-in-class or new biology-based drug discovery approaches and innovative platform technologies. The firm prioritizes assets with strategic alignment to the parent organization’s pipeline. The firm evaluates a broad range of modalities, including biologics, oncolytic viruses, and small molecules, and considers cell and gene therapy on an opportunistic basis. The primary therapeutic focus is oncology, with additional interest in immunology, allergy, musculoskeletal, and orphan indications.
While the firm is primarily therapeutics-focused, the firm may selectively review medical device, diagnostic, or digital health technologies where there is strong strategic alignment.
From a company and management team perspective, the firm seeks teams with strong sector expertise. With the backing of an established oncology development organization, the firm provides financial support and facilitates strategic partnerships to help advance novel research and high-potential drug candidates toward commercialization. The firm may request regional options or rights on a case-by-case basis.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment